COMPLETED

Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.

Official Title

Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients

Quick Facts

Study Start:2021-11-17
Study Completion:2025-07-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05226793

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Enoxaparin dose (appropriate for kidney function)
  2. * Charlson comorbidity index (CCI) score
  3. * Padua prediction score for risk of VTE
  4. * IMPROVE \[International Medical Prevention Registry on VTE\] bleeding risk assessment score
  5. * ICU status
  6. * Number of thromboembolic events
  7. * Length of stay
  8. * Readmissions for DVT and/or PE
  9. * In-hospital mortality with associated DVT or PE
  1. * Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:
  2. * Bleeding events
  3. * Type of bleeding event

Contacts and Locations

Principal Investigator

Betina Daniel, PharmD
PRINCIPAL_INVESTIGATOR
Methodist

Study Locations (Sites)

Methodist Richardson Medical Center
Richardson, Texas, 75082
United States

Collaborators and Investigators

Sponsor: Methodist Health System

  • Betina Daniel, PharmD, PRINCIPAL_INVESTIGATOR, Methodist

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-17
Study Completion Date2025-07-22

Study Record Updates

Study Start Date2021-11-17
Study Completion Date2025-07-22

Terms related to this study

Additional Relevant MeSH Terms

  • Venous Thromboembolism